project id: TCGA-PRAD; case submitter id: TCGA-VN-A88I; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.74; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.13; rna integrity number: 7.3; age at index: 59; days to birth: -21576; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1952; age at diagnosis: 21576; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 269.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 730; initial weight: 260.0; sample id: 1f2b8ff0-5945-4e70-a24c-fe0bdb0c962e; sample submitter id: TCGA-VN-A88I-01A; portion id: 133ed570-2ed7-48c2-9c68-c64a7e780d8d; portion submitter id: TCGA-VN-A88I-01A-11; slide id: b75fb23a-72c1-40d7-91da-09f7efab5296; slide submitter id: TCGA-VN-A88I-01A-01-TSA; percent lymphocyte infiltration: 60.0; percent monocyte infiltration: 5.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0; section location: TOP;